UNSPSC 51363002: Tixadil

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4L1E450W. European Medicines Agency schedules Tixadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11125MIG. Tixadil generally arises in the molecular formula C24H25NS.

The term TIXADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) TIXADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tixadil under HS 29349990 and SITC 51579. As of Q4 2014, TIXADIL remains the US FDA Preferred Term for this commodity. Tixadil bears US NLM identifiers UMLS ID C2699958 and NCI Concept Code C76948. SMILES: S1C2C(C(CCNC(CC3CCCCC3)C)C3C1CCCC3)CCCC2.

UNSPSC 51363002 Tixadil (Commodity) represents pharmaceutical products and related medical supplies that state and local governments procure for emergency response, public health, and community wellness programs. Recent opportunities show state and local buyers acquiring naloxone and drug deactivation systems for overdose prevention and harm reduction, generic pharmaceuticals through multistate cooperative purchasing consortia, and exploring direct-to-manufacturer prescription fulfillment models to improve cost management and supply chain efficiency. The code spans county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that coordinate procurement across member jurisdictions. Work under the code includes competitive bidding for specific pharmaceutical products with defined National Drug Codes and packaging requirements, requests for information to evaluate vendor capabilities in direct contracting and outcomes-based pricing models, and proposals to establish manufacturer contracts with authorized wholesalers.

Recent activity appears concentrated in Florida and Texas, with broader multistate coordination through Minnesota's MMCAP cooperative. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendors to include all shipping and delivery costs in fixed-fee pricing; the contract includes potential FEMA funding and a three-month probationary period. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs without PBMs or GPOs, seeking vendor experience with self-insured group health plans and value-based contracting models. Minnesota's MMCAP (in cooperation with Oregon) issued RFP S1070000015802 on January 20, 2026 (responses due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, evaluating proposals on pricing competitiveness (75 percent weight), regulatory compliance including cGMP and DSCSA certification, and EDI capability, with awards effective July 1, 2026.